Immunome Inc. (IMNM) - Dilution Analysis

10-Q filing | 113.1M shares outstanding

10-Q filing | 88.0M shares outstanding

10-Q filing | 87.0M shares outstanding

10-Q filing | 79.4M shares outstanding

10-K filing | 43.3M shares outstanding

8-K filing: Immunome, Inc. announced a public offering of 19,354,839 shares of common stock at a price of $7.75 per share, with gross proceeds of $150.0 million, with the offering expected to close on January 31, 2025. ($150.0M proceeds)

10-Q filing | 43.3M shares outstanding

8-K filing: Immunome, Inc. issued 1,805,502 shares of common stock to Zentalis Pharmaceuticals, Inc. as partial consideration for the Asset Purchase Agreement, under which Immunome purchased certain intellectual property relating to Zentalis' antibody-drug conjugate (ADC) platform technology, ROR1 antibodies and ADCs targeting ROR1.

10-Q filing | 43.3M shares outstanding

10-Q filing | 59.7M shares outstanding

10-K filing | 43.3M shares outstanding

8-K filing: Immunome, Inc. announced a public offering of 10,000,000 shares of common stock at a price of $20.00 per share, with gross proceeds of $200 million before deducting underwriting discounts and commissions, and the underwriters have an option to purchase up to 1,500,000 additional shares. ($200.0M proceeds)

8-K filing: Immunome, Inc. entered into an Asset Purchase Agreement with Ayala Pharmaceuticals, Inc. to acquire Ayala's AL101 and AL102 programs, issuing 2,175,489 shares of Company common stock to Ayala as part of the consideration. ($20.0M proceeds)

8-K filing: Immunome, Inc. entered into a license agreement with Zentalis Pharmaceuticals, Inc. and issued 2,298,586 shares of its common stock to Zentalis as partial consideration for the rights licensed under the agreement. ($35.0M proceeds)

S-3 filing: This S-3 filing registers 21,690,871 shares of common stock for resale by selling stockholders who acquired the shares in a private placement.

10-Q filing | 12.2M shares outstanding

8-K filing: Immunome closed a PIPE Financing on October 2, 2023, issuing 21,690,871 shares of common stock for approximately $125.0 million. The company also filed amendments to its Amended and Restated Certificate of Incorporation, increasing the number of authorized shares of Immunome common stock from 200,000,000 to 300,000,000. ($125.0M proceeds)

10-Q filing | 12.2M shares outstanding

8-K filing: Immunome, Inc. entered into a merger agreement with Morphimmune Inc. and Ibiza Merger Sub, Inc., and concurrently entered into subscription agreements for a PIPE Financing, selling 21,690,871 shares of Immunome common stock for approximately $125.0 million. ($125.0M proceeds)

10-Q filing | 12.2M shares outstanding

10-K filing | 12.1M shares outstanding

10-Q filing | 12.1M shares outstanding

10-Q filing | 12.1M shares outstanding

10-Q filing | 12.1M shares outstanding

10-K filing | 11.5M shares outstanding

10-Q filing | 10.6M shares outstanding

S-3 filing: Immunome, Inc. files an S-3 registration statement to register an indeterminate number of shares of common stock and preferred stock, depositary shares, debt securities, rights, warrants, or units with a maximum aggregate offering price of $200,000,000.

10-Q filing | 11.8M shares outstanding

S-1/A filing: This S-1/A filing relates to the possible resale of up to 2,521,683 shares of common stock previously issued and issuable upon exercise of warrants.

S-1/A filing: This S-1/A filing registers 2,521,683 shares of common stock for resale by selling stockholders, previously issued and issuable upon exercise of warrants. The company will not receive proceeds from the sale of these shares, but may receive proceeds from warrant exercises.

10-Q filing | 10.7M shares outstanding

S-1 filing: Registration of 2,535,196 shares of common stock for resale by selling stockholders; shares were previously issued and are issuable upon exercise of warrants.

8-K filing: Immunome, Inc. entered into a Securities Purchase Agreement to issue 1,000,000 shares of common stock and warrants to purchase 500,000 shares at $27.00 per unit, with gross proceeds of approximately $27.0 million. ($27.0M proceeds)

10-K filing | 10.6M shares outstanding

10-Q filing | 1.1M shares outstanding

8-K filing: Immunome, Inc. closed its initial public offering of 3,250,000 shares of its common stock at a price of $12.00 per share, resulting in gross proceeds of $39.0 million. ($39.0M proceeds)

S-1/A filing: This S-1/A filing registers common stock for sale, with Ladenburg Thalmann and Chardan acting as book-running managers. The company estimates expenses of approximately $3,000,000 related to the offering.

S-1 filing: This is an S-1 filing for an initial public offering of common stock with a proposed maximum aggregate offering price of $30,000,000.